KRRO News and Press, Korro Bio Inc.

2026-03-13 09:03:22 ET Steve Seehouse from Cantor Fitzgerald issued a price target of $22.00 for KRRO on 2026-03-13 11:27:00. The adjusted price target was set to $22.00. At the time of the announcement, KRRO was trading at $11.5. The overall price target consensus is at...

2026-03-13 08:15:10 ET Raymond James analyst issues OUTPERFORM recommendation for KRRO on March 13, 2026 08:26AM ET. The previous analyst recommendation was Market Perform. KRRO was trading at $11.5 at issue of the analyst recommendation. The overall analyst consensus : ...

2026-03-12 16:59:01 ET More on Korro Bio Korro Bio, Inc. (KRRO) Analyst/Investor Day Transcript Korro Bio, Inc. (KRRO) Analyst/Investor Day - Slideshow Korro Bio, Inc. (KRRO) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Korro announce...

Nominated KRRO-121 development candidate for the potential treatment of hyperammonemia in patients with urea cycle disorders and hepatic encephalopathy Advanced GalNAc-conjugated oligonucleotide for alpha-1 antitrypsin deficiency; on track to nominate development candidate second quarter of 2026...

2026-03-09 08:26:39 ET More on Korro Bio Korro Bio, Inc. (KRRO) Analyst/Investor Day Transcript Korro Bio, Inc. (KRRO) Analyst/Investor Day - Slideshow Korro Bio, Inc. (KRRO) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Seeking Alpha&...

Financing led by new investor Venrock Healthcare Capital Partners, with participation from new and existing investors Proceeds support the achievement of value inflection points for multiple RNA editing programs including reporting clinical data for: KRRO-121 for hyperammonemia in patients...

CAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company developing a new class of genetic medicines based on editing RNA for rare and highly prevalent diseases, today announced that Ram Aiyar, Ph.D., Chief Executive Officer and Presi...

2026-01-29 15:42:29 ET Korro Bio, Inc. (KRRO) Analyst/Investor Day January 27, 2026 8:00 AM EST Company Participants Ram Aiyar - CEO, President, Interim CFO, Principal Financial Officer & Director Todd Chappell - Chief Operating Officer Loic Vincent - Chief Sci...

2026-01-29 06:15:10 ET H.C. Wainwright analyst issues BUY recommendation for KRRO on January 29, 2026 11:08AM ET. The previous analyst recommendation was Buy. KRRO was trading at $11.69 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Cur...

2026-01-28 19:04:40 ET Yasmeen Rahimi from Piper Sandler issued a price target of $30.00 for KRRO on 2026-01-28 23:12:24. The adjusted price target was set to $30.00. At the time of the announcement, KRRO was trading at $11.69. The overall price target consensus is at $1...